nach oben

Pathology & Oncology Research

Erschienen in:

01.10.2013 | Review

Alternatives for the Intensive Follow-Up After Curative Resection of Colorectal Cancer. Potential Novel Biomarkers for the Recommendations

verfasst von: Enikő Orosz, István Ember, Katalin Gombos, László Tóth, Ádám Tarpay, Ákos Pap, Szabolcs Ottó

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Early diagnosis of recurrence and metastasis of colorectal cancer following surgery of curative intent is of vital importance in terms of survival and quality of life. The consistent implementation of appropriate patient follow-up strategy is therefore essential. Debates over the methodology, evaluation and strategy of follow-up have been known for many years, and continue today. By introducing several follow-up models, the present paper offers different options featuring certain individual, national and international, conceptual and financial aspects. Colorectal cancer is an important public health concern due to its destructive nature and frequency, it is therefore essential to develop new monitoring strategies, involving new biomarkers and extensive clinical validation. Since the recurrence rate is very high in high-risk patients, the improvement of individual patient risk estimates and the utilization of a corresponding follow-up model require broad international co-operation and common practice, along with the determination of optimal levels of evidence.

Bray F, Sankila F, Ferlay J et al (2002) Estimates ef cancer incidence and mortality in Europe in 1995. Eur J Cancer 38:99–166CrossRefPubMed

Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592CrossRefPubMed

Ottó S (2003) Cancer epidemiology in Hungary and the Béla Johan National Program for the decade of health. Pathol Oncol Res 2:126–130CrossRef

Yang L, Fujimoto J, Qiu D et al (2010) Trends in cancer mortality in the elderly in Japan, 1970–2007. Ann Oncol 21:389–396CrossRefPubMed

Bosetti C, Levi F, Rosato V et al (2011) Recent trends in colorectal cancer mortality in Europe. Int J Cancer 129:180–191CrossRefPubMed

Malvezzi M, Bertuccio P, Levi F et al (2012) European cancer mortality predictions for the year 2012. Ann Oncology 23:1044–1052CrossRef

Verdecchia A, Francisci S, Brenner H et al (2007) Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784–796CrossRefPubMed

Majek O, Gondos A, Jansen L et al (2012) Survival from colorectal cancer in Germany in the early 2 Ist century. Br J Cancer 106:1875–1880CrossRefPubMed

Rachet B, Woods LM, Mitry E et al (2008) Cancer survival in England and Wales at the end of the 20th century. Br J Cancer 99:S2–S10CrossRefPubMed

10.

Aslam MI, Taylor K, Pringle JH et al (2009) MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg 96:702–710CrossRefPubMed

11.

La Vecchia C, Bosetti C, Lucchini F et al (2010) Cancer mortality in Europe, 2000–2004, and overview of trends since 1975. Ann Oncol 21:1323–1360CrossRefPubMed

12.

Tusnády G, Gaudi I, Rejtő L et al (2008) Survival chances of Hungarian cancer patients in the National Cancer Registry. Hungarian Oncol 52:339–349

13.

Olesen F, Hansen RP, Vedsted P (2009) Delay in diagnosis: the experience in Denmark. Br J Cancer 101:55–58CrossRef

14.

Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516CrossRefPubMed

15.

Baca B, Beart RW, Etzioni DA (2011) Surveillance after colorectal cancer resection: a systematic review. Dis Colon Rectum 54:1036–1048CrossRefPubMed

16.

Levin B, Liberman DA, McFarland B et al (2008) American Cancer Society Colorectal Cancer Advisory Group. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multy-Society Task Force on colorectal cancer, and the American College of Radiology. Gastroenterology 134:1570–1595CrossRefPubMed

17.

Dunn BK, Wagner PD, Anderson D et al (2010) Molecular markers for early detection. Semin Oncol 37:224–242CrossRefPubMed

18.

Diamandis EP (2010) Cancer Biomarkers: can we turn recent failures into success? J Natl Cancer Inst 102:1462–1467CrossRefPubMed

19.

Bertagnolli MM (2009) The forest and the trees:pathways and proteins as colorectal cancer biomarkers. J Clin Oncol 27:5866–5867CrossRefPubMed

20.

Jung Y, Lee S, Choi H-S et al (2011) Clinical validation of colorectal cancer biomarkers identified from bioinformatics analysis of public expression data. Clin Cancer Res 17:700–709CrossRefPubMed

21.

Gutman S, Kessler LG (2006) The US Food and Drug Administration perspective on cancer biomarker development. Nature Rev/Cancer 6:565–571

22.

McShane LM, Hayes DF (2012) Publication of tumos marker research result: the necesity for complete and transparent reporting. J Clin Oncol 30:4223–4232CrossRefPubMed

23.

Labianca R, Nordlinger B, Beretta GD et al (2010) Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 21(Suppl 5):v70–v77CrossRefPubMed

24.

Griesenberg D, Nürnberg R, Bahlo M et al (1999) CEA, TPS, CA 19–9 and CA 72–4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer. Anticancer Res 19:2443–2450PubMed

25.

Hohnbec JRL, Topolcan O, Pikner R et al (2000) The significance of CEA, CA 19–9 and CA 72–4 in the detection of colorectal carcinoma recurrence. Anticancer Res 20:5237–5244

26.

Lane JM, Chow E, Young GP et al (2010) Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia. Gastroenterology 139:1918–1926CrossRefPubMed

27.

Morris AM, Gryfe R, Thorson AG et al (2011) Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons, and the American Society of Colorectal Surgeons: evidence based review in surgery – colorectal surgery. Dis Colon Rectum 54:1598–1600CrossRef

28.

Engstrom PF, Arnoletti JP, Benson AP et al (2009) NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Cancer Netw 7:778–831

29.

Criblez D (2007) Revidierte Konsensus-Empfehlungen zur Nachsorge nach koloskopischer Polypektomie und nach kurativ operiertem kolorektalem Karzinom. Schweiz Med Forum 7:994–999

30.

Viehl CT, Ochsner A, von Holzen U et al (2010) Inadequate quality of surveillance after curative surgery for colon cancer. Ann Surg Oncol 17:2663–2669CrossRefPubMed

31.

Tsitikis VL, Maliraldy K, Green EA et al (2009) Postoperative surveillance recommendations for early stage colon cancer based on result from the clincal outcomes of surgical therapy trial. J Clin Oncol 27:3671–3676CrossRef

32.

Desch CE, Benson AB III, Somerfield MR et al (2005) Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 23:8512–8519CrossRefPubMed

33.

Fora A, Patta A, Attwood K et al (2012) Intensive radiographic and biomarker surveillance in stage II and III colorectal cancer. Oncology 82:41–47CrossRefPubMed

34.

Andreoni B, Chiappa A, Bertani E et al (2007) Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients. World J Surg Oncol 5:73CrossRefPubMed

35.

Jeffrey M, Hickey BE, Hider PN (2007) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev CD002200

36.

Yakabe T, Nakafusa Y, Sumi K et al (2010) Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol 17:2349–2356CrossRefPubMed

37.

Chang GJ, Kaiser AM, Mills S et al (2012) Practice parameters for the management of colon cancer. Dis Colon Rectum 55:831–843CrossRefPubMed

38.

Borie F, Daures JP, Millat B et al (2004) Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study. J Gastrointest Surg 8:552–558CrossRefPubMed

39.

Hara M, Sato M, Takahashi H et al (2010) Does serum Carcinoembryonic Antigen elevation in patients with postoperatve stage II colorectal cancer indicate recurrence ? Comparison with stage III. J Surg Oncol 102:154–157CrossRefPubMed

40.

Renehan AG, Egger M, Saunders MP et al (2002) Impact on survival of intensive follow-up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. Br Med J 324:813CrossRef

41.

Holt A, Nelson RA, Lai L (2010) Surveillance with serial serum carcinoembryonic levels detect colorectal cancer recurrences in patients who are initial nonsecretors. Am Surg 76:1100–1103PubMed

42.

Mulder SA, Van Leerdam ME, Ouwendijk RJ et al (2007) Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scand J Gastroenterol 42:66–71CrossRefPubMed

43.

Herzlinger RE, Parsa-Parsi R (2004) Consumer-driven health care: lessons from Switzerland. JAMA 292:1213–1220CrossRefPubMed

44.

Grossmann I, de Bock GH, van de Velde et al (2007) Resalts of a national survey among Dutch surgeons treating patients with colorectal carcinoma. Current opinion about follow-up, treatment of metastasis, and reasons to revise follow-up practice. Colorect Dis 9:782–792CrossRef

45.

Locker G, Hamilton S, Harris J et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313–5327CrossRefPubMed

46.

Van der Geest LGM, Krijnen P, Wouters MWJM et al (2012) Improved guideline compliance after a 3-year audit of multidisciplinary colorectal cancer care in the western part of the Netherlands. J Surg Oncol 106:1–9CrossRefPubMed

47.

Ho JM, Juurlink DN, Cavalcanti RB (2010) Hypokalemia following polyethylene glycol-based bowel preparation for colonoscopy in older hospitalized patients with significant comorbidities. Ann Pharmacother 44:466–470CrossRefPubMed

48.

Miller A, Steele S (2012) Novell molecular screening approaches in corectal cancer. J Surg Oncol 105:459–467CrossRefPubMed

49.

Stoop EM, de Haan MC, de Wijkerslooth TR et al (2012) Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 13:55–64CrossRefPubMed

50.

Barbas AS, Turley RS, Mantyh CR et al (2012) Effect of surgeon specialization on long-term survival following. Colon cancer resection at an NCI - designated cancer center. J Surg Oncol 106:219–223CrossRefPubMed

51.

Jones RP, Jackson R, Dunne DFJ et al (2012) Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg 99:477–486CrossRefPubMed

52.

Lyass S, Zamir G, Matot I et al (2001) Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol 78:17–21CrossRefPubMed

53.

Gomez D, Sangha VK, Morris-Stiff G (2010) Outcomes of intensive surveillance after resection of hepatic colorectal metastases. Br J Surg 97:1552–1560CrossRefPubMed

54.

Tarantino I, Warschkow R, Worni M et al (2012) Elevated preoperative CEA is associated with worse survival in stage I-III cancer patiens. Br J Cancer 107:266–274CrossRefPubMed

55.

Lin JK, Lin CC, Yang SH et al (2011) Early postoperative CEA level is a better prognostic indicator than is preoperative CEA level in predicting prognosis of patiens with curable colorectal cancer. Int J Colorectal Dis 26(9):1135–1141CrossRefPubMed

56.

Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95CrossRef

57.

Saijo N (2012) Critical comments for roles of biomarkers. Cancer Treat Rev 38:63–67CrossRefPubMed

58.

Trapé J, Fiella X, Alsina-Donadeu et al (2011) Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 49(10):1605–1620CrossRefPubMed

59.

Canil CM, Tannok IF (2002) Doctor’s dilemma: incorporating tumor markers into clinical decision-making. Semin Oncol 29:286–293CrossRefPubMed

60.

Kern SE (2012) Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Ress 72(23):6097–6101CrossRef

61.

Lecomte T, Ceze N, Dorval É et al (2010) Circulating free tumor DNA and colorectal cancer. Gastroen Clin Biol 34:662–681CrossRef

62.

Ryan BM, Lefort F, McManus R et al (2003) A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperatve folow-up. Gut 52:101–108CrossRefPubMed

63.

Rose JS, Serna DS, Martin KL (2012) Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma. Cancer 118:6243–6252CrossRefPubMed

64.

De Vos T, Tetzner R, Model F et al (2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55:1337–1346CrossRef

65.

Matsubara N (2012) Epigenetic regulation and colorectal cancer. Dis Colon Rectum 55:96–104CrossRefPubMed

66.

Cassinotti E, Melson J, Ligetti T et al (2012) DNA methylation patters in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer 131:1153–1157CrossRefPubMed

67.

Ahlquist DA, Zou H, Domanico M et al (2012) Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterol 142:248–256CrossRef

68.

Miranda E, Bianchi P, Destro A et al (2013) Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases. Cancer 119:266–276CrossRefPubMed

69.

Baldus SE, Schaefer KL, Engels R et al (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16:790–799CrossRefPubMed

70.

Cohen SJ, Punt CJA, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221CrossRefPubMed

71.

Lowes LE, Hegley BD, Keeney M et al (2012) User-defined protein marker assay development for characterization of circulating tumor cells using the Cell Search® System. Cytometry Part A 81A:983–995CrossRef

72.

Sato N, Hayashi N, Imamura Y et al (2012) Usefulness of Transcription-Reserve Transcription Concerted reaction method for detecting ciculating tumor cells in patiens with colorectal cancer. Ann Surg Oncol 19:2060–2065CrossRefPubMed

73.

Flamini E, Mercatali L, Nanni O et al (2006) Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 12:6985–6988CrossRefPubMed

74.

Phillipp AB, Stieber P, Nagel D et al (2012) Prognostic role of methylated free circulating DNA in colorectal cancer. Int J Cancer 131:2308–2319CrossRef

75.

Chan C-C, Fan C-W, Kuo Y-B et al (2010) Multiple serological biomarkers for colorectal cancer detection. Int J Cancer 126:1683–1690CrossRefPubMed

76.

Lawrie CH, Gal S, Dunlop HM et al (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141:672–675CrossRefPubMed

77.

Huang Z, Huang D, Ni S et al (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127:118–126CrossRefPubMed

78.

Brase J, Wuttig D, Kuner R et al (2010) Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9:306CrossRefPubMed

79.

Shibuya H, Linuma H, Shimada R et al (2010) Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 79:313–320CrossRefPubMed

80.

Nishida N, Yamashita S, Minori K et al (2012) MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-Fluorouracil in colorectal cancer cells. Ann Surg Oncol 19:3065–3071CrossRefPubMed

81.

Schwarzenbach H, Hoon DSB, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nature Rev/Cancer 11:426–436

82.

Kosaka N, Iguchi H, Ochiya T (2010) Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101:2087–2092CrossRefPubMed

83.

Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 105:10513–10518CrossRefPubMed

84.

Nair VS, Maeda LS, Ioannidis JPA (2012) Clinical outcome prediction by microRNAs in human cancer. A systematic review. Reviews/JNCI 104:528–540

85.

Chen C, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006CrossRefPubMed

Titel: Alternatives for the Intensive Follow-Up After Curative Resection of Colorectal Cancer. Potential Novel Biomarkers for the Recommendations
verfasst von: Enikő Orosz
István Ember
Katalin Gombos
László Tóth
Ádám Tarpay
Ákos Pap
Szabolcs Ottó
Publikationsdatum: 01.10.2013
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 4/2013
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-013-9672-7

Springer Medizin

Alternatives for the Intensive Follow-Up After Curative Resection of Colorectal Cancer. Potential Novel Biomarkers for the Recommendations

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

A New Ki-67 / E-Cadherin Cocktail Reduces Inter-observer Variation of the Calculated Proliferative Index

Prolyl Isomerase Pin1 Regulated Signaling Pathway Revealed by Pin1 +/+ and Pin1 −/− Mouse Embryonic Fibroblast Cells

Tumor-Related Gene Changes in Immunosuppressive Syrian Hamster Cholangiocarcinoma

miR-135a/b Modulate Cisplatin Resistance of Human Lung Cancer Cell Line by Targeting MCL1

Overexpression of Metastasis-Associated in Colon Cancer-1 Associated with Poor Prognosis in Patients with Esophageal Cancer

Overexpression of CD73 in Prostate Cancer is Associated with Lymph Node Metastasis

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie